GlobeNewswire

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
06/10/2026
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver [...]
Stryker announces leadership succession
06/10/2026
Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kevin Lobo to transition to Executive Chair of the Board of Directors Current President and COO Spencer Stiles appointed Chief Executive Officer Leadership transition [...]
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
06/10/2026
Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology [...]
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
06/10/2026
Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC) MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- [...]
Oak Hill Bio Appoints Joerg Hipp, PhD as Chief Translational Science Officer
06/10/2026
CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- OHB Pediatrics Ltd d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the appointment of Joerg Hipp, PhD as Chief Translational [...]
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
06/10/2026
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research Market
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced the launch of two research-focused peptide products, GHK-Cu and the Wolverine Stack , expanding its product offering for Canadian laboratories, [...]
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
06/10/2026
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use [...]
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
06/10/2026
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer [...]
MediciNova to Participate in the Maxim Growth Summit
06/10/2026
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
06/10/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will [...]
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata [...]
Transactions in connection with share buy-back program
06/10/2026
Company announcement no. 38 - 26 06 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El [...]
Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026
06/10/2026
Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation Dr. Lara Campana to present preclinical data on intravenous [...]
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months Regina Hodits from Angelini Ventures to join Rouge [...]
RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01
06/10/2026
Dr Koh brings extensive infectious disease and clinical development expertise as RQ Bio prepares to advance RQB01 into the clinic Senior appointments across CMC, clinical operations and programme management further [...]
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
06/10/2026
Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional [...]
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum